Drug Discovery
Continued from page 77
23 Brown, D. Future pathways for combinatorial chemistry. Mol Divers 2, 217-222 (1996). 24 Drew, KLM et al. Size estimation of chemical space: how big is it? J Pharm Pharm 64, 490-495 (2012). 25 Reymond, JL, Awale, M. Exploring chemical space for drug discovery using the chemical universe database. ACS Chem Neurosci 3, 649-57 (2012). 26 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed on 14 February 2013;
http://www.accessdata.fda.gov/ scripts/cder/ob/
default.cfm. 27 In European Commission, Pharmaceutical Sector Inquiry, Preliminary Report (DG Competition Staff Working Paper), November 28, 2008. 28 Nisen, M. The 10 Best Selling Prescription Drugs in the United States. In the Business Insider, June 28, 2012;
http://www.businessinsider.co m/10-best-selling-blockbuster- drugs-2012-
6?op=1#ixzz2KzPtaOWz. 29 Mullin, R. Before the Storm. Chem Eng News 89, 12-18 (2011). 30 Cragg, GM et al. The impact of the United Nations Convention on Biological Diversity on natural products research. Nat Prod Rep 29, 1407-1423 (2012).
A call to revive natural product research Will the Pharma industry answer the call? Most likely not as reflected in their recent activities of consolidations, layoffs and site closures. I would also speculate that they would eventually eliminate the ‘R’ from their R&D efforts and shift it towards the public sector; in turn, government agencies, academics and non-for-profit research organisa- tions will answer the call and hopefully revive nat- ural product research through a global initiative to benefit mankind. Combined, they would provide Pharma with unprecedented access to the largest research enterprise in the world at little or no cost to them. Academic and non-for-profit screening operations throughout the world are better posi- tioned than ever to screen natural products as extracts or purified molecules. The global nature of this initiative would require special collaborative agreements protecting the rights of all parties involved, especially those biodiversity rich source countries providing access to their resources and in return, be rewarded in a fair and equitable manner. Such efforts have been ongoing for many years now with the hope that we are indeed close to the ratification of the Nagoya Protocol, which requires signatures from 50 countries30.
Acknowledgements
I wish to thank members of my lab and colleagues at the centre for fruitful discussions over the past 10 years. The HTS Lab is partially supported by William H. Goodwin and Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center of the Memorial Sloan-Kettering Cancer Center, the William Randolph Hearst Fund in Experimental
Dr Hakim Djaballah, molecular pharmacologist and technologist, has been the Director of the HTS Core Facility at Memorial Sloan-Kettering Cancer Center since its establishment in 2003. In 1992, he received his PhD in biochemistry from the University of Leicester, England. He was the recip- ient of the 2007 Robots and Vision User Recognition Award.
Therapeutics, the Lillian S. Wells Foundation and by a NIH/NCI Cancer Center Support Grant 5 P30 CA008748-44.
DDW
Beckman Coulter, Inc BioTek Instruments, Inc BMG LABTECH GmbH
Cellular Dynamics International CISBIO International SA CyBio AG
Douglas Scientific LLC
49 25 53 21 6
54 45
ADVERTISEMENT INDEX 4
eBioscience, Inc ForteBio, Inc HTStec Ltd
IntelliCyt Corporation Labcyte, Inc
Life Science Network Life Technologies Corporation
15 23 42 28 13
26-27
Promega Corporation Seahorse Bioscience, Inc Select Biosciences Ltd
Sigma-Aldrich Corporation Singulex, Inc
Tecan Schweiz AG
40-41 8
58-59 OBC 17,37 IFC-3
78
Drug Discovery World Spring 2013
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80